9 March 2018, Munich, Germany – On 23–24 April 2018, decision makers from biotech, pharma and finance will meet in Munich for the 11th BioVaria to learn about emerging life-science trends and initiate partnerships with academic inventors, entrepreneurs and technology transfer professionals from all over Europe.
This year, 17 technology transfer organizations from seven nations have brought together an outstanding portfolio of high-potential commercial opportunities including innovative diagnostic and therapeutic approaches as well as platform technologies. Over 60 peer-selected, patent-protected technologies originating from as many research institutes, universities and university hospitals will be featured.
The expanded Startup Pitch & Partner program provides additional opportunities for entrepreneurs and venture capitalists, with interactive pitches, an inspiring keynote and one-on-one mentoring sessions.
Technology highlights from Ascenion’s academic partners are:
- New method for assessing cortical bone microstructure using 3D ultrasound spectroscopy (Charité – Universitätsmedizin Berlin)
The approach may revolutionize the diagnosis of osteoporosis and the monitoring of therapeutic effects during treatment or drug development. Unlike the current diagnostic standard, bone mineral density (BMD), it can precisely detect micro-structural changes in cortical bone, is radiation-free and can be implemented in standard ultrasound devices that are widely used in doctors’ offices and health centres.
- Game-changing genome editing approach (Max Delbrück Center for Molecular Medicine in the Helmholtz Association)
The novel genetic replacement strategy overcomes a key constraint of conventional homologous recombination techniques: it works with non-dividing cells and achieves replacement rates of about 30%. It holds strong therapeutic potential, e.g. in cell-line creation and developing ex vivotreatments of genetic disorders.
- Novel treatment for sepsis in newborns (Hannover Medical School)
S100-alarmins present a highly innovative and promising approach for the prevention and treatment of septic disease in newborns. The approach is based on seminal research demonstrating that these proteins help prevent hyperinflammatory responses after birth. It may prove particularly valuable to premature babies and newborns delivered by Caesarean section who have low S100-alarmin levels and an increased risk of sepsis.
- Innovative nerve sheath tumour therapy (Leibniz Institute on Aging - Fritz Lipmann Institute)
In vivo data support the potential of the recombinant soluble EGF-like domain of neuregulin 1 as novel protein replacement therapy for certain tumours of the nervous system. It can effectively inhibit tumour growth and has a benign side-effect profile – unlike available treatment options which have devastating effects on patients' quality of life. Its safety is further supported by Phase II clinical data obtained in a different indication.
- Therapeutic antibodies against neurodegenerative disorders (German Center for Neurodegenerative Diseases)
Novel antibodies against C9orf72 poly-GA proteins were shown to interfere with two key mechanisms of disease progression in certain rare neurodegenerative disorders: first with the intracellular aggregation of poly-GA, and second with the seeding and spreading of such aggregates to other cells. It is a promising new opportunity for C9orf72 patients.
A preview of all technologies selected for BioVaria 2018 is now available online. Please visit www.biovaria.org
T: +49 89 318814-22
Ascenion GmbH, Herzogstraße 64, 80803 Munich, GERMANY
Bavarian Ministry of Economic Affairs and Media, Energy and Technology
BioM, Boehringer Ingelheim, Johnson & Johnson Innovation, Life Science Inkubator / Photonik Inkubator, Abbvie, Else Kröner-Fresenius-Stiftung, Helmholtz Association of German Research Centers, Vossius & Partner, WuXi AppTec, HERTIN & Partner, Kador & Partner, LSP, 24IP Law Group, 3D-PharmXchange, ttopstart
Technology transfer partners:
Ascenion, Austria Wirtschaftsservice Gesellschaft, Bayerische Patentallianz, BTO Bergen Teknologioverføring, Centre for Transfer of Biomedical Technologies, DKFZ - German Cancer Research Center, DZIF - German Center for Infection Research, EMBLEM Technology Transfer, IOCB Tech, KU Leuven - Centre for Drug Design and Discovery, Lead Discovery Center, LifeArc, Max Planck Innovation, Netval, PROvendis, TechnologieAllianz, University of Pardubice
ASTP-Proton, BIO Deutschland
Going Public, LABIOTECH.eu, transkript
BioVaria brings together Europe’s top scientists and technology transfer professionals with potential licensees and investors from the international biopharmaceutical industry.
Further information: www.biovaria.org
Key features of BioVaria 2018:
- Unique gathering of Europe's top scientists, entrepreneurs, technology transfer professionals, investors and industry representatives
- Presentation of more than 60 licensable technologies and spin-offs originating from public research institutions and universities across Europe
- Focus on patent-protected, commercially attractive opportunities covering therapeutics, diagnostics and research tools in the fields of cancer, infectious diseases, metabolism, autoimmune and neurodegenerative disorders, and in other disease areas
- Interactive format combining 10-min oral presentations with an interactive exhibition and plenty networking opportunities
- Start-up Pitch & Partner program with competition for the BioVaria Start-up Award, inspiring keynote and one-on-one mentoring
- Ample space to discuss scientific details face-to-face with the inventors and entrepreneurs
- Jointly organized by Ascenion and a selected group of leading European technology transfer organizations
Ascenion is an independent technology transfer company focussing on the life sciences. It is partner to over 30 research organizations, universities and university hospitals in Germany and Europe, including life-science institutes of the Helmholtz and Leibniz Associations, the Charité, Hannover Medical School, the Medical University of Innsbruck and the University Medical Center Göttingen. Ascenion’s multidisciplinary, industry-experienced team works closely with its partners to tap the potential of their research by identifying promising results, obtaining patent protection, and turning pure science into applied technology. Particular strengths are spin-off support and project development, where early-stage projects are transformed into assets that attract potential investors and licensees. This has led to the founding of numerous new companies and the transfer of innovative medical approaches into approved drugs, changing the lives of thousands of patients. Profits from Ascenion’s operative business and exit proceeds flow via its parent company, the LifeScience Foundation for the Promotion of Science and Research, to fund further translational research at its partner institutes.
Further information at: www.ascenion.de